Acta Scientific Biotechnology

Short Communication Volume 1 Issue 12

Molecular Targets and Biotechnological Exploration on Corona-Virus and Multi-Drug Resistant Bacteria

Asit Kumar Chakraborty*

Associate Professor of Biochemistry, OIST, Department of Biotechnology, Vidyasagar University, Midnapore, West Bengal, India

*Corresponding Author: Asit Kumar Chakraborty, Associate Professor of Biochemistry, OIST, Department of Biotechnology, Vidyasagar University, Midnapore, West Bengal, India.

Received: November 25, 2020; Published: November 30, 2020


  Invisible SARS-CoV-2 27kb single (+)-stranded RNA virus (120nm) has crossed limit by killing 3 millions and affecting 600 millions [1]. Severe COVID-19 is more common in adults aged ~70 years and older and in individuals with comorbidities such as hypertension, diabetes, cardiovascular disease, and chronic respiratory disease [2]. Indian Government as well as other G-20 nations declared war against Corona virus. Coronavirus has structural proteins (S, M, N, E) and two large polyproteins which degraded into sixteen non-structural proteins (nsp1-16) [3]. No new targeted drug was discovered and vaccine is only new hope. Presently, at least ten vaccine candidates are in stage-III clinical trials on 20 - 40 thousand human worldwide [4-8]. It is expected that India should be starting vaccination in the middle of 2021 with a cost of few hundred to few thousand per dose. Vaccine usually is a protein or synthetic peptides from Corona virus that can elicits humoral antibody (IgG) as well as T-cell mediated ability to destroy virus.



  1. Li Q., et al. “Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia”. The New England Journal of Medicine 13 (2020): 1199-1207.
  2. Lu R., et al. “Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding”. Lancet 395 (2020): 565-574.
  3. Wu F., et al. “Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China”. Bio Rxiv (2020).
  4. Anderson EJ., et al. “Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults”. The New England Journal of Medicine (2020).
  5. Zhu FC., et al. “Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial”. Lancet 396 (2020): 479-488.
  6. Logunov DY., et al. “Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia”. Lancet 396 (2020): 887-897.
  7. Ramasamy MN., et al. “Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial”. Lancet (2020).
  8. Van Doremalen N., et al. “ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques”. Nature 586 (2020): 578-582.
  9. Chakraborty AK. “Coronavirus Nsp2 Protein Homologies to the Bacterial DNA Topoisomerase I and IV Suggest Nsp2 Protein is an Unique RNA Topoisomerase with Novel Target for Drug and Vaccine Development”. Virology and Mycology 9 (2020): 185.
  10. Chakraborty AK. “Unusual Enzymes in Corona Virus Genome and their Roles in Pathogenicity Control and Drug Design”. EC Emergency Medicine and Critical Care 9 (2020): 45-50.
  11. Fu L., et al. “Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease”. Nature Communications 1 (2020): 4417.
  12. Chakraborty AK., et al. “Multidrug Resistant Bacteria with Activated and Diversified MDR Genes in Kolkata Water: Ganga Action Plan and Heterogeneous Phyto Antibiotics Tackling Superbug Spread in India”. American Journal of Advanced Drug Delivery Therapy 1 (2018): 2.
  13. Tiri B., et al. “Antimicrobial Stewardship Program, COVID-19 and Infection Control: Spread of Carbapenem-Resistant Klebsiella Pneumoniae Colonization in ICU COVID-19 Patients. What Did Not Work?” Journal of Clinical Medicine 9 (2020): 2744.
  14. Vaillancourt M and Jorth P. “The Unrecognized Threat of Secondary Bacterial Infections with COVID-19”. M Bio4 (2020): e01806-e018020.
  15. Cantón R., et al. “Antimicrobial resistance in ICUs: an update in the light of the COVID-19 pandemic”. Current Opinion in Critical Care5 (2020): 433-441.
  16. Cole J and Barnard E. “The Impact of the COVID-19 Pandemic on Healthcare Acquired Infections with Multidrug Resistant Organisms”. American Journal of Infection Control 1 (2020): 5726.
  17. Chakraborty AK., et al. “An abundant new saponin-polybromophenol antibiotic (CU1) from Cassia fistula bark targeting RNA polymerase”. Bio Rxiv (2020).


Citation: Asit Kumar Chakraborty. “Molecular Targets and Biotechnological Exploration on Corona-Virus and Multi-Drug Resistant Bacteria". Acta Scientific Biotechnology 1.12 (2020): 25-26.


Acceptance rate36%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US